Targeting histone deacetylases in T-cell lymphoma

References

• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–1159.
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. Apmis. 2007;115:1039–1059.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6:637–656.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol. 2010;5:196–208.
   PubMedGoogle Scholar
• Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci. 2003;983:84–100.
   PubMed Web of Science ®Google Scholar
• Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81–120.
   PubMed Web of Science ®Google Scholar
• Marsoni S, Damia G, Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics. 2008;3:164–171.
   PubMed Web of Science ®Google Scholar
• Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90:85–94.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, et al. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21.
   PubMed Web of Science ®Google Scholar
• Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338:17–31.
   PubMed Web of Science ®Google Scholar
• Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238–243.
   PubMed Web of Science ®Google Scholar
• Lichtman MA, Beutler E, Kipps TJ, et al. Williams hematology. In: Anonymous. 7th ed. USA: McGraw-Hill Medical; 2006.
   Google Scholar
• NCCN clinical practice guidelines in oncology: Non-hodgkin's lymphomas V.3.2016. National Comprehensive Cancer Network. https://www.nccn.org/store/login/login.aspx; https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
   Google Scholar
• Cancer facts & figures. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf; 2015.
   Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC). Blood. 2007;110:1713–1722.
   PubMed Web of Science ®Google Scholar
• Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008;22:979–996.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised international society for cutaneous lymphomas/european organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28:4730–4739.
   PubMed Web of Science ®Google Scholar
• Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18:5051–5060.
   PubMed Web of Science ®Google Scholar
• Alberti-Violetti S, Talpur R, Schlichte M, et al. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. Clin Lymphoma Myeloma Leuk. 2015;15:e105–e112.
   Google Scholar
• Vose J, Armitage J, Weisenburger D. International T-ell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117:6756–6767.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Anonymous. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008. p. 439.
   Google Scholar
• Horwitz SM. Management of peripheral T-cell non-Hodgkin's lymphoma. Curr Opin Oncol. 2007;19:438–443.
   PubMed Web of Science ®Google Scholar
• Foss FM, Carson KR, Pinter-Brown L, et al. Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment. Blood. 2012;120:Abstract 1614.
   Web of Science ®Google Scholar
• Abouyabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.
   PubMedGoogle Scholar
• Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–113.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123:2636–2644.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–173.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98:2865–2868.
   PubMed Web of Science ®Google Scholar
• Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009;54:688–698.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Brammer JE, Li Y, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5:e357.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636–4643.
   PubMed Web of Science ®Google Scholar
• Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Investig Dermatol. 2005;125:1045–1052.
   PubMed Web of Science ®Google Scholar
• Conti C, Leo E, Eichler GS, et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 2010;70:4470–4480.
   PubMed Web of Science ®Google Scholar
• Bates SE, Eisch R, Ling A, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015;170:96–109.
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14:4500–4510.
   PubMed Web of Science ®Google Scholar
• Istodax (romidepsin) [package insert] 2016. Available from: http://www.istodax.com/wp-content/uploads/ISTODAX_PackageInsert.pdf
   Google Scholar
• Zolinza (vorinostat) [package insert] 2015. Available from: https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf
   Google Scholar
• Beleodaq (belinostat) [package insert] 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf
   Google Scholar
• Whittaker SJ, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Foss FM, Duvic M, Lerner A, et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement. J Clin Oncol. 2014;32:Abstract 8575.
   PubMed Web of Science ®Google Scholar
• Duvic M, Kim YH, Rook AH, et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) and prior treatment with systemic chemotherapy: subanalysis from the pivotal phase II study. T-Cell Lymphoma Forum. 2014; Abstract TS15_3.
   Google Scholar
• Kim YH, Demierre MF, Kim EJ, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma. 2013;54:284–289.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–636.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.
   PubMed Web of Science ®Google Scholar
• Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). Hematol Oncol. [Epub ahead of print]. doi: 10.1002/hon.2320.
   Google Scholar
• Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410–5417.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–5834.
   PubMed Web of Science ®Google Scholar
• Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014;2:16.
   PubMedGoogle Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–39.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115.
   PubMed Web of Science ®Google Scholar
• Duvic M, Kim YH, Kuzel TM, etet al. The systemic effects of vorinostat in patients (pts) with cutaneous T-cell lymphoma (CTCL): post-hoc analysis in pts with high blood tumor burden. Blood. 2009;114:Abstract 1709.
   Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168:811–819.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–2499.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Horwitz SM, Zinzani PL, etet al. Safe and effective treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and low baseline platelet counts with belinostat. Blood. 2014;124:Abstract 3075.
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapesd or refractory peripheral T-cell lymphoma. J Clin Oncol. 2013;31(suppl.):Abstract 8525.
   Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766–1771.
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Zhu J, et al. Phase II study of chidamide, a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2015;126:Abstract 1513.
   Web of Science ®Google Scholar
• Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin's lymphoma. J Clin Oncol. 2007;25:3500.
   Google Scholar
• Sharma S, Vogelzang NJ, Beck J, et al. Phase I pharmacokinetic and pharmacodynamic study of once-weekly i.v. panobinostat (LBH589). European Cancer Conference (ECCO 14) 2007;Poster presentation.
   Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49:386–394.
   PubMed Web of Science ®Google Scholar
• Kristeleit R, Fong P, Aherne GW, et al. Histone deacetylase inhibitors: emerging anticancer therapeutic agents? Clin Lung Cancer. 2005;7 Suppl 1:S19–S30.
   Google Scholar
• Molife R, Fong P, Scurr M, et al. HDAC inhibitors and cardiac safety. Clin Cancer Res. 2007;13:1068.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res. 2008;14:6663–6673.
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14:804–810.
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12:3997–4003.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Margolin K, Ferber S, et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5:57–60.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923–3931.
   PubMed Web of Science ®Google Scholar
• FIscher T, Patnaik A, Bhalla K, etet al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumros and hematologic malignancies. J Clin Oncol. 2005;23:3106.
   Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12:3762–3773.
   PubMed Web of Science ®Google Scholar
• Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for KATP channel. Clin Cancer Res. 2013;19:3095–3104.
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718–728.
   PubMed Web of Science ®Google Scholar
• Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003;37:1276–1286.
   PubMed Web of Science ®Google Scholar
• Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist. 2002;7:65–72.
   PubMed Web of Science ®Google Scholar
• Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009;114:3709.
   Web of Science ®Google Scholar
• Dupuis J, Morschhauser F, Ghesquieres H, et al. Combination of romidepsin with cyclosphosphamide, doxorubicin, vinrcristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: A non-randomised, phase 1b/2 study. Lancet Hematol. 2015;2:e160–e165.
   PubMed Web of Science ®Google Scholar
• Delarue R, Zinzani PL, Hertzberg MS, et al. ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma. J Clin Oncol. 2013;31:Abstract TPS8616.
   Web of Science ®Google Scholar
• Oki Y, Younes A, Copeland A, et al. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013;162:138–141.
   PubMed Web of Science ®Google Scholar
• Johnston PB, Cashen AF, Nikolinakos PG, et al. Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the bel-CHOP phase 1 trial. Blood. 2015;126:Abstract 253.
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Westin JR, et al. High response rate of romidepsin in combination with ICE (ifosfamide, carboplatin and etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma: updates of phase I trial. Blood. 2015;126:Abstract 3987.
   Web of Science ®Google Scholar
• Budde LE, Zhang MM, Shustov AR, et al. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol. 2013;161:183–191.
   PubMed Web of Science ®Google Scholar
• Targretin (bexarotene) [package insert] 2013.
   Google Scholar
• Dummer R, Beyer M, Hymes K, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma. 2012;53:1501–1508.
   PubMed Web of Science ®Google Scholar
• Revlimid (lenalidomide) [package insert] 2015. Available from: http://www.revlimid.com/wp-content/uploads/full-prescribing-information.pdf
   Google Scholar
• Witzig TE, Vose JM, Moore TD, et al. Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood. 2007;110:Abstract 2560.
   Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Cosenza M, Civallero M, Fiorcari S, et al. Romidepsin synergizes with lenalidomide in T cell lymphoma cell lines by increasing reactive oxygen species and modulating PI3K/AKT and MAPK/ERK signaling pathways. Blood. 2014;124:Abstract 1778.
   Web of Science ®Google Scholar
• Cosenza M, Civallero M, Fiorcari S, et al. Romidepsin and lenalidomide show a synergistic effect in T-cell lymphoma cell lines. Blood. 2013;122:Abstract 5148.
   Google Scholar
• Lunning MA, Ruan J, Nair S, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relaped/refractory lymphoma and myeloma: phase 1 results. J Clin Oncol. 2014;32:Abstract 8582.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Lunning MA, Ruan J, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma. Hematol Oncol. 2015;33:Abstract 016.
   Google Scholar
• Hopfinger G, Nosslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol. 2014;93:459–462.
   PubMed Web of Science ®Google Scholar
• Friedberg J, Mahadevan D, Jung J, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts 2011;118:Abstract 95.
   Google Scholar
• Barr PM, Li H, Spier CM, et al. U.S. intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). J Clin Oncol. 2014;32(15_suppl.):Abstract 8523.
   Web of Science ®Google Scholar
• Zullo K, Guo Y, Cooke L, et al. The investigational aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin. Blood. 2014;124:Abstract 4493.
   Web of Science ®Google Scholar
• Fanale MA, Hagemeister FB, Fayad L, et al. A phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B- and T-cell lymphomas. Blood. 2014;124:Abstract 1744.
   Web of Science ®Google Scholar
• Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165–5173.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341–347.
   PubMed Web of Science ®Google Scholar
• Oki Y, Buglio D, Fanale M, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19:6882–6890.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:4293–4297.
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441–3449.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–3852.
   PubMed Web of Science ®Google Scholar
• Sutheesophon K, Kobayashi Y, Takatoku MA, et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 2006;115:78–90.
   PubMed Web of Science ®Google Scholar
• Kikuchi J, Wada T, Shimizu R, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406–417.
   PubMed Web of Science ®Google Scholar
• Heider U, Rademacher J, Lamottke B, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol. 2009;82:440–449.
   PubMed Web of Science ®Google Scholar
• Farydak (panobinostat) [package insert] 2016. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/farydak.pdf
   Google Scholar
• Goh Y, Hwang WYK, Diong CP, et al. A phase 2 study of panobinostat (PAN) in combination with bortezomib (BTZ) in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL). Blood. 2014;124:Abstract 503.
   Google Scholar
• Dedes KJ, Dedes I, Imesch P, et al. Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs. 2009;20:321–333.
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62:4916–4921.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol. 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor O, Jurczak W, et al. Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): results from the pivotal BELIEF trial. 12th International Conference on Malignant Lymphoma; 2013.
   Google Scholar